Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00890396 · ClinicalTrials.gov registry record

Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)

A clinical trial, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Completed
Registry status
163
Enrollment target

NCT00890396: Completed study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

NCT00890396 is a clinical trial that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 163 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00890396 has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

COMPLETED
Registry status
163 participants
Enrollment target

Study Summary

Sickle cell anemia (SCA) is an inherited blood disorder that can cause organ damage. The BABY HUG study is evaluating the use of the medication hydroxyurea at preventing organ damage in children with SCA. The purpose of this follow-up study is to evaluate the long-term effects of hydroxyurea in children who have participated in the BABY HUG study.

Primary Outcome

The change in splenic function from the randomized control trial baseline measurement was one of the primary outcomes. The change in splenic function (worse vs not-worse) was compared between the randomized treatment groups (hydroxyurea vs placebo). The change in splenic function from baseline to 48 months was defined as worse if it changed from normal to decreased or absent, or decreased to absent; and not worse if it changed from decreased to decreased, normal to normal, decreased to normal, a

Interventions

  • DRUG Hydroxyurea

Trial Details

FieldValue
Enrollment Target 163 participants
Start Date 2008-09
Est. Completion 2011-12

What the finished NCT00890396 record still lists

NCT00890396 is an observational study that tracks outcomes without assigning an intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 1 intervention - of which Hydroxyurea is the first listed.

NCT00890396 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00890396 about?

NCT00890396 is a clinical study titled "Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)". Sickle cell anemia (SCA) is an inherited blood disorder that can cause organ damage. The BABY HUG study is evaluating the use of the medication hydroxyurea at preventing organ damage in children with SCA. The purpose of this follow-up study is to evaluate the long-term effects of hydroxyurea in chil...

What is the current status of trial NCT00890396?

This trial is currently completed. The enrollment target is 163 participants. The study started on 2008-09. Estimated completion is 2011-12.

What interventions are being tested in trial NCT00890396?

The interventions under investigation include: Hydroxyurea (DRUG).

Who is sponsoring clinical trial NCT00890396?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03180268 · 163 participants · Phase 3

    Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

  • NCT04862221 · 163 participants · Phase 2

    TReatment for ImmUne Mediated PathopHysiology

  • NCT05702229 · 163 participants · Phase 2

    Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  • NCT06137118 · 163 participants · Phase 1

    AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00890396, the US trial registry maintained by the National Library of Medicine. NCT00890396 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.